arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CURIS INC

CRIS
$4.34 ▼ -0.13 (-3.02%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

CURIS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $57.1M
Dividend Yield
Revenue Growth -13.4%
Op. Margin -60.5%
ROIC -82.6%
FCF / Share $-2.07
Trailing P/E
Price / Book 10.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.44M
↓ -13.4%
Net Income Profit after all expenses
$-7.58M
↑ +82.5%
Operating Margin Operating profit as % of sales
-60.5%
↑ +85.2% 4th
FCF / Share Free cash flow per share
$-2.07
↑ +67.1%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
6
Financial Health
38
Cash Quality
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters